Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) Target Price at $255.65

Charles River Laboratories International, Inc. (NYSE:CRL) has received an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $255.6471.

CRL has been the topic of several analyst reports. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research note on Monday, July 20th. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a research report on Monday, August 10th. Finally, JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $289.40 on Friday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The stock has a fifty day moving average of $256.31 and a two-hundred day moving average of $202.66. The company has a market capitalization of $13.82 billion, a price-to-earnings ratio of -59.67, a PEG ratio of 2.83 and a beta of 1.40. Charles River Laboratories International has a fifty-two week low of $144.26 and a fifty-two week high of $303.30.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts anticipate that Charles River Laboratories International will post 11.33 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, CEO Birgit Girshick sold 6,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at approximately $10,080,038.70. This represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 33,561 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at approximately $9,478,800. The trade was a 51.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 165,990 shares of company stock valued at $42,606,388. 1.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds have recently modified their holdings of CRL. Continuum Advisory LLC purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $30,000. Los Angeles Capital Management LLC purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth $42,000. Sfam LLC acquired a new position in Charles River Laboratories International in the fourth quarter valued at $43,000. Elyxium Wealth LLC acquired a new position in Charles River Laboratories International in the fourth quarter valued at $46,000. Finally, Geneos Wealth Management Inc. grew its position in Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 145 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.